

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Patent



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61K 36/00, C12P 21/06, 19/34 C12Q 1/00		(10) International Publication Number: WO 93/01276	
(21) International Application Number: PCT/US92/03797		(40) International Publication Date: 21 January 1993 (21.01.93)	
(22) International Filing Date: 10 July 1992 (10.07.92)		(52) Invention and (53) Technical Field (for US only): CLARE, Robert A. (US) 5,108,810; 5,108,811; 5,108,812; 5,108,813; (US) 5,108,814; 5,108,815; 5,108,816; 5,108,817; (US) 5,108,818; 5,108,819; 5,108,820; 5,108,821; (US) 5,108,822; 5,108,823; 5,108,824; 5,108,825; (US) 5,108,826; 5,108,827; 5,108,828; 5,108,829; (US) 5,108,830; 5,108,831; 5,108,832; 5,108,833; (US) 5,108,834; 5,108,835; 5,108,836; 5,108,837; (US) 5,108,838; 5,108,839; 5,108,840; 5,108,841; (US) 5,108,842; 5,108,843; 5,108,844; 5,108,845; (US) 5,108,846; 5,108,847; 5,108,848; 5,108,849; (US) 5,108,850; 5,108,851; 5,108,852; 5,108,853; (US) 5,108,854; 5,108,855; 5,108,856; 5,108,857; (US) 5,108,858; 5,108,859; 5,108,860; 5,108,861; (US) 5,108,862; 5,108,863; 5,108,864; 5,108,865; (US) 5,108,866; 5,108,867; 5,108,868; 5,108,869; (US) 5,108,870; 5,108,871; 5,108,872; 5,108,873; (US) 5,108,874; 5,108,875; 5,108,876; 5,108,877; (US) 5,108,878; 5,108,879; 5,108,880; 5,108,881; (US) 5,108,882; 5,108,883; 5,108,884; 5,108,885; (US) 5,108,886; 5,108,887; 5,108,888; 5,108,889; (US) 5,108,890; 5,108,891; 5,108,892; 5,108,893; (US) 5,108,894; 5,108,895; 5,108,896; 5,108,897; (US) 5,108,898; 5,108,899; 5,108,900; 5,108,901; (US) 5,108,902; 5,108,903; 5,108,904; 5,108,905; (US) 5,108,906; 5,108,907; 5,108,908; 5,108,909; (US) 5,108,910; 5,108,911; 5,108,912; 5,108,913; (US) 5,108,914; 5,108,915; 5,108,916; 5,108,917; (US) 5,108,918; 5,108,919; 5,108,920; 5,108,921; (US) 5,108,922; 5,108,923; 5,108,924; 5,108,925; (US) 5,108,926; 5,108,927; 5,108,928; 5,108,929; (US) 5,108,930; 5,108,931; 5,108,932; 5,108,933; (US) 5,108,934; 5,108,935; 5,108,936; 5,108,937; (US) 5,108,938; 5,108,939; 5,108,940; 5,108,941; (US) 5,108,942; 5,108,943; 5,108,944; 5,108,945; (US) 5,108,946; 5,108,947; 5,108,948; 5,108,949; (US) 5,108,950; 5,108,951; 5,108,952; 5,108,953; (US) 5,108,954; 5,108,955; 5,108,956; 5,108,957; (US) 5,108,958; 5,108,959; 5,108,960; 5,108,961; (US) 5,108,962; 5,108,963; 5,108,964; 5,108,965; (US) 5,108,966; 5,108,967; 5,108,968; 5,108,969; (US) 5,108,970; 5,108,971; 5,108,972; 5,108,973; (US) 5,108,974; 5,108,975; 5,108,976; 5,108,977; (US) 5,108,978; 5,108,979; 5,108,980; 5,108,981; (US) 5,108,982; 5,108,983; 5,108,984; 5,108,985; (US) 5,108,986; 5,108,987; 5,108,988; 5,108,989; (US) 5,108,990; 5,108,991; 5,108,992; 5,108,993; (US) 5,108,994; 5,108,995; 5,108,996; 5,108,997; (US) 5,108,998; 5,108,999; 5,109,000; 5,109,001; (US) 5,109,002; 5,109,003; 5,109,004; 5,109,005; (US) 5,109,006; 5,109,007; 5,109,008; 5,109,009; (US) 5,109,010; 5,109,011; 5,109,012; 5,109,013; (US) 5,109,014; 5,109,015; 5,109,016; 5,109,017; (US) 5,109,018; 5,109,019; 5,109,020; 5,109,021; (US) 5,109,022; 5,109,023; 5,109,024; 5,109,025; (US) 5,109,026; 5,109,027; 5,109,028; 5,109,029; (US) 5,109,030; 5,109,031; 5,109,032; 5,109,033; (US) 5,109,034; 5,109,035; 5,109,036; 5,109,037; (US) 5,109,038; 5,109,039; 5,109,040; 5,109,041; (US) 5,109,042; 5,109,043; 5,109,044; 5,109,045; (US) 5,109,046; 5,109,047; 5,109,048; 5,109,049; (US) 5,109,050; 5,109,051; 5,109,052; 5,109,053; (US) 5,109,054; 5,109,055; 5,109,056; 5,109,057; (US) 5,109,058; 5,109,059; 5,109,060; 5,109,061; (US) 5,109,062; 5,109,063; 5,109,064; 5,109,065; (US) 5,109,066; 5,109,067; 5,109,068; 5,109,069; (US) 5,109,070; 5,109,071; 5,109,072; 5,109,073; (US) 5,109,074; 5,109,075; 5,109,076; 5,109,077; (US) 5,109,078; 5,109,079; 5,109,080; 5,109,081; (US) 5,109,082; 5,109,083; 5,109,084; 5,109,085; (US) 5,109,086; 5,109,087; 5,109,088; 5,109,089; (US) 5,109,090; 5,109,091; 5,109,092; 5,109,093; (US) 5,109,094; 5,109,095; 5,109,096; 5,109,097; (US) 5,109,098; 5,109,099; 5,109,100; 5,109,101; (US) 5,109,102; 5,109,103; 5,109,104; 5,109,105; (US) 5,109,106; 5,109,107; 5,109,108; 5,109,109; (US) 5,109,110; 5,109,111; 5,109,112; 5,109,113; (US) 5,109,114; 5,109,115; 5,109,116; 5,109,117; (US) 5,109,118; 5,109,119; 5,109,120; 5,109,121; (US) 5,109,122; 5,109,123; 5,109,124; 5,109,125; (US) 5,109,126; 5,109,127; 5,109,128; 5,109,129; (US) 5,109,130; 5,109,131; 5,109,132; 5,109,133; (US) 5,109,134; 5,109,135; 5,109,136; 5,109,137; (US) 5,109,138; 5,109,139; 5,109,140; 5,109,141; (US) 5,109,142; 5,109,143; 5,109,144; 5,109,145; (US) 5,109,146; 5,109,147; 5,109,148; 5,109,149; (US) 5,109,150; 5,109,151; 5,109,152; 5,109,153; (US) 5,109,154; 5,109,155; 5,109,156; 5,109,157; (US) 5,109,158; 5,109,159; 5,109,160; 5,109,161; (US) 5,109,162; 5,109,163; 5,109,164; 5,109,165; (US) 5,109,166; 5,109,167; 5,109,168; 5,109,169; (US) 5,109,170; 5,109,171; 5,109,172; 5,109,173; (US) 5,109,174; 5,109,175; 5,109,176; 5,109,177; (US) 5,109,178; 5,109,179; 5,109,180; 5,109,181; (US) 5,109,182; 5,109,183; 5,109,184; 5,109,185; (US) 5,109,186; 5,109,187; 5,109,188; 5,109,189; (US) 5,109,190; 5,109,191; 5,109,192; 5,109,193; (US) 5,109,194; 5,109,195; 5,109,196; 5,109,197; (US) 5,109,198; 5,109,199; 5,109,200; 5,109,201; (US) 5,109,202; 5,109,203; 5,109,204; 5,109,205; (US) 5,109,206; 5,109,207; 5,109,208; 5,109,209; (US) 5,109,210; 5,109,211; 5,109,212; 5,109,213; (US) 5,109,214; 5,109,215; 5,109,216; 5,109,217; (US) 5,109,218; 5,109,219; 5,109,220; 5,109,221; (US) 5,109,222; 5,109,223; 5,109,224; 5,109,225; (US) 5,109,226; 5,109,227; 5,109,228; 5,109,229; (US) 5,109,230; 5,109,231; 5,109,232; 5,109,233; (US) 5,109,234; 5,109,235; 5,109,236; 5,109,237; (US) 5,109,238; 5,109,239; 5,109,240; 5,109,241; (US) 5,109,242; 5,109,243; 5,109,244; 5,109,245; (US) 5,109,246; 5,109,247; 5,109,248; 5,109,249; (US) 5,109,250; 5,109,251; 5,109,252; 5,109,253; (US) 5,109,254; 5,109,255; 5,109,256; 5,109,257; (US) 5,109,258; 5,109,259; 5,109,260; 5,109,261; (US) 5,109,262; 5,109,263; 5,109,264; 5,109,265; (US) 5,109,266; 5,109,267; 5,109,268; 5,109,269; (US) 5,109,270; 5,109,271; 5,109,272; 5,109,273; (US) 5,109,274; 5,109,275; 5,109,276; 5,109,277; (US) 5,109,278; 5,109,279; 5,109,280; 5,109,281; (US) 5,109,282; 5,109,283; 5,109,284; 5,109,285; (US) 5,109,286; 5,109,287; 5,109,288; 5,109,289; (US) 5,109,290; 5,109,291; 5,109,292; 5,109,293; (US) 5,109,294; 5,109,295; 5,109,296; 5,109,297; (US) 5,109,298; 5,109,299; 5,109,300; 5,109,301; (US) 5,109,302; 5,109,303; 5,109,304; 5,109,305; (US) 5,109,306; 5,109,307; 5,109,308; 5,109,309; (US) 5,109,310; 5,109,311; 5,109,312; 5,109,313; (US) 5,109,314; 5,109,315; 5,109,316; 5,109,317; (US) 5,109,318; 5,109,319; 5,109,320; 5,109,321; (US) 5,109,322; 5,109,323; 5,109,324; 5,109,325; (US) 5,109,326; 5,109,327; 5,109,328; 5,109,329; (US) 5,109,330; 5,109,331; 5,109,332; 5,109,333; (US) 5,109,334; 5,109,335; 5,109,336; 5,109,337; (US) 5,109,338; 5,109,339; 5,109,340; 5,109,341; (US) 5,109,342; 5,109,343; 5,109,344; 5,109,345; (US) 5,109,346; 5,109,347; 5,109,348; 5,109,349; (US) 5,109,350; 5,109,351; 5,109,352; 5,109,353; (US) 5,109,354; 5,109,355; 5,109,356; 5,109,357; (US) 5,109,358; 5,109,359; 5,109,360; 5,109,361; (US) 5,109,362; 5,109,363; 5,109,364; 5,109,365; (US) 5,109,366; 5,109,367; 5,109,368; 5,109,369; (US) 5,109,370; 5,109,371; 5,109,372; 5,109,373; (US) 5,109,374; 5,109,375; 5,109,376; 5,109,377; (US) 5,109,378; 5,109,379; 5,109,380; 5,109,381; (US) 5,109,382; 5,109,383; 5,109,384; 5,109,385; (US) 5,109,386; 5,109,387; 5,109,388; 5,109,389; (US) 5,109,390; 5,109,391; 5,109,392; 5,109,393; (US) 5,109,394; 5,109,395; 5,109,396; 5,109,397; (US) 5,109,398; 5,109,399; 5,109,400; 5,109,401; (US) 5,109,402; 5,109,403; 5,109,404; 5,109,405; (US) 5,109,406; 5,109,407; 5,109,408; 5,109,409; (US) 5,109,410; 5,109,411; 5,109,412; 5,109,413; (US) 5,109,414; 5,109,415; 5,109,416; 5,109,417; (US) 5,109,418; 5,109,419; 5,109,420; 5,109,421; (US) 5,109,422; 5,109,423; 5,109,424; 5,109,425; (US) 5,109,426; 5,109,427; 5,109,428; 5,109,429; (US) 5,109,430; 5,109,431; 5,109,432; 5,109,433; (US) 5,109,434; 5,109,435; 5,109,436; 5,109,437; (US) 5,109,438; 5,109,439; 5,109,440; 5,109,441; (US) 5,109,442; 5,109,443; 5,109,444; 5,109,445; (US) 5,109,446; 5,109,447; 5,109,448; 5,109,449; (US) 5,109,450; 5,109,451; 5,109,452; 5,109,453; (US) 5,109,454; 5,109,455; 5,109,456; 5,109,457; (US) 5,109,458; 5,109,459; 5,109,460; 5,109,461; (US) 5,109,462; 5,109,463; 5,109,464; 5,109,465; (US) 5,109,466; 5,109,467; 5,109,468; 5,109,469; (US) 5,109,470; 5,109,471; 5,109,472; 5,109,473; (US) 5,109,474; 5,109,475; 5,109,476; 5,109,477; (US) 5,109,478; 5,109,479; 5,109,480; 5,109,481; (US) 5,109,482; 5,109,483; 5,109,484; 5,109,485; (US) 5,109,486; 5,109,487; 5,109,488; 5,109,489; (US) 5,109,490; 5,109,491; 5,109,492; 5,109,493; (US) 5,109,494; 5,109,495; 5,109,496; 5,109,497; (US) 5,109,498; 5,109,499; 5,109,500; 5,109,501; (US) 5,109,502; 5,109,503; 5,109,504; 5,109,505; (US) 5,109,506; 5,109,507; 5,109,508; 5,109,509; (US) 5,109,510; 5,109,511; 5,109,512; 5,109,513; (US) 5,109,514; 5,109,515; 5,109,516; 5,109,517; (US) 5,109,518; 5,109,519; 5,109,520; 5,109,521; (US) 5,109,522; 5,109,523; 5,109,524; 5,109,525; (US) 5,109,526; 5,109,527; 5,109,528; 5,109,529; (US) 5,109,530; 5,109,531; 5,109,532; 5,109,533; (US) 5,109,534; 5,109,535; 5,109,536; 5,109,537; (US) 5,109,538; 5,109,539; 5,109,540; 5,109,541; (US) 5,109,542; 5,109,543; 5,109,544; 5,109,545; (US) 5,109,546; 5,109,547; 5,109,548; 5,109,549; (US) 5,109,550; 5,109,551; 5,109,552; 5,109,553; (US) 5,109,554; 5,109,555; 5,109,556; 5,109,557; (US) 5,109,558; 5,109,559; 5,109,560; 5,109,561; (US) 5,109,562; 5,109,563; 5,109,564; 5,109,565; (US) 5,109,566; 5,109,567; 5,109,568; 5,109,569; (US) 5,109,570; 5,109,571; 5,109,572; 5,109,573; (US) 5,109,574; 5,109,575; 5,109,576; 5,109,577; (US) 5,109,578; 5,109,579; 5,109,580; 5,109,581; (US) 5,109,582; 5,109,583; 5,109,584; 5,109,585; (US) 5,109,586; 5,109,587; 5,109,588; 5,109,589; (US) 5,109,590; 5,109,591; 5,109,592; 5,109,593; (US) 5,109,594; 5,109,595; 5,109,596; 5,109,597; (US) 5,109,598; 5,109,599; 5,109,600; 5,109,601; (US) 5,109,602; 5,109,603; 5,109,604; 5,109,605; (US) 5,109,606; 5,109,607; 5,109,608; 5,109,609; (US) 5,109,610; 5,109,611; 5,109,612; 5,109,613; (US) 5,109,614; 5,109,615; 5,109,616; 5,109,617; (US) 5,109,618; 5,109,619; 5,109,620; 5,109,621; (US) 5,109,622; 5,109,623; 5,109,624; 5,109,625; (US) 5,109,626; 5,109,627; 5,109,628; 5,109,629; (US) 5,109,630; 5,109,631; 5,109,632; 5,109,633; (US) 5,109,634; 5,109,635; 5,109,636; 5,109,637; (US) 5,109,638; 5,109,639; 5,109,640; 5,109,641; (US) 5,109,642; 5,109,643; 5,109,644; 5,109,645; (US) 5,109,646; 5,109,647; 5,109,648; 5,109,649; (US) 5,109,650; 5,109,651; 5,109,652; 5,109,653; (US) 5,109,654; 5,109,655; 5,109,656; 5,109,657; (US) 5,109,658; 5,109,659; 5,109,660; 5,109,661; (US) 5,109,662; 5,109,663; 5,109,664; 5,109,665; (US) 5,109,666; 5,109,667; 5,109,668; 5,109,669; (US) 5,109,670; 5,109,671; 5,109,672; 5,109,673; (US) 5,109,674; 5,109,675; 5,109,676; 5,109,677; (US) 5,109,678; 5,109,679; 5,109,680; 5,109,681; (US) 5,109,682; 5,109,683; 5,109,684; 5,109,685; (US) 5,109,686; 5,109,687; 5,109,688; 5,109,689; (US) 5,109,690; 5,109,691; 5,109,692; 5,109,693; (US) 5,109,694; 5,109,695; 5,109,696; 5,109,697; (US) 5,109,698; 5,109,699; 5,109,700; 5,109,701; (US) 5,109,702; 5,109,703; 5,109,704; 5,109,705; (US) 5,109,706; 5,109,707; 5,109,708; 5,109,709; (US) 5,109,710; 5,109,711; 5,109,712; 5,109,713; (US) 5,109,714; 5,109,715; 5,109,716; 5,109,717; (US) 5,109,718; 5,109,719; 5,109,720; 5,109,721; (US) 5,109,722; 5,109,723; 5,109,724; 5,109,725; (US) 5,109,726; 5,109,727; 5,109,728; 5,109,729; (US) 5,109,730; 5,109,731; 5,109,732; 5,109,733; (US) 5,109,734; 5,109,735; 5,109,736; 5,109,737; (US) 5,109,738; 5,109,739; 5,109,740; 5,109,741; (US) 5,109,742; 5,109,743; 5,109,744; 5,109,745; (US) 5,109,746; 5,109,747; 5,109,748; 5,109,749; (US) 5,109,750; 5,109,751; 5,109,752; 5,109,753; (US) 5,109,754; 5,109,755; 5,109,756; 5,109,757; (US) 5,109,758; 5,109,759; 5,109,760; 5,109,761; (US) 5,109,762; 5,109,763; 5,109,764; 5,109,765; (US) 5,109,766; 5,109,767; 5,109,768; 5,109,769; (US) 5,109,770; 5,109,771; 5,109,772; 5,109,773; (US) 5,109,774; 5,109,775; 5,109,776; 5,109,777; (US) 5,109,778; 5,109,779; 5,109,780; 5,109,781; (US) 5,109,	

CONTINUOUS CELL LINE AND VACCINE AGAINST
AVIAN COCCIDIA

Field of the Invention

5 The present invention relates generally to a virus-free continuous cell line adapted for propagation of avian coccidia. More particularly, the invention relates to the use of the cell line for the production of vaccine antigens for prophylactic treatment of poultry against coccidiosis.

Background of the Invention

Coccidiosis is an enteric disease of domestic and wild livestock causing acute morbidity resulting in decreased growth and feed utilization. The avian coccidia (Genus *Eimeria*) are obligate intracellular protozoan parasites of the intestinal epithelium. These parasites have a monoxenous life cycle and exhibit a high degree of host-species and tissue specificity. For poultry, coccidial infection results in economic loss from stunting and skin discoloration. Overall, the combination of losses due to coccidiosis and prophylactic medication results in a cost to the poultry industry in excess of \$300 million annually [Dentforth and Augustine, *Animal Nutrition and Health*, pp. 18-21 (August 1985)].

2

Thousands of coccidian oocysts may be ingested at one time by a single host. Once ingested the parasites invade specific intestinal cells where they may undergo several rounds of asexual replication followed by gametogony before millions of new parasites are shed in the litter to complete the life cycle. Different species of poultry suffer from infections caused by different coccidia species. The domestic fowl (*Gallus domesticus*) can be infected by any of the coccidia *Eimeria tenella*, *E. necatrix*, *E. brunetti*, *E. maxima*, *E. acanthina* and *E. praecox*. The following coccidia are implicated in infections of turkeys (*Meleagris*): *Eimeria meleagridis*, *E. dispersa*, *E. meleagridis*, *E. gallonyx*, *E. adenoides*, *E. innocua* and *E. subrostrata*. Domestic ducks (*Anas*) suffer from infections caused by *Eimeria matricaria* and also, it is believed, by *Eimeria anatis* which they can acquire from wild ducks (*Anas platyrhynchos*). Geese (*Anser*) can suffer from infections caused by *Eimeria anseris*, *E. necans* and *E. parvula*, and in addition it is believed that domestic geese can acquire infections from Canada geese caused by *Eimeria hutchinsii*, *E. stricklandi* and *E. fulva*.

Immunity to coccidiosis is reported to be highly species-specific and a manifestation of cell-mediated processes [K. E. Rose, in "Biology of the Coccidia", P. L. Long, ed., University Park Press,

Baltimore, pp.328-373 (1982)). Natural exposure to Eimerian oocysts elicits complete protective immunity; this response appears to result primarily from the development of intracellular parasite stages instead of extracellular sporozoites or merozoites [M. Jenkins et al, Infect. Immun., 59:4042-4048 (1991)]. Although a few oocysts may confer protection to subsequent challenge, this primary exposure impacts adversely on weight gain, feed utilization and skin pigment retention.

Current methods of control involve primarily chemotherapeutic treatment with anticoccidial drugs mixed into the feed. Effective compounds have included sulphonamides, quinolones and polyyether ionophorous antibiotics [See, e.g., L. R. McDougald, in "Biology of the Coccidia", pp. 373-427 (1982)]. These compounds appear to affect parasite development at different stages of their lifecycle. Over time, however, drug resistant strains of parasites have evolved, thus severely limiting a drug's usefulness [T. K. Jeffers, Avian Dis., 18:74 (1974); T. K. Jeffers, Avian Dis., 18:331 (1974); and H. D. Chapman, Vet. Parasit., 15:11-27 (1984)].

Other less established control measures include the actual feeding of live oocysts from well characterized wild type or attenuated strains of several Eimeria species to chickens to establish immunity.

Cocci-Vac [Starvin Labs] utilizes controlled numbers of specific species of chicken Eimeria added to feed or water or administered individually [See, e.g., S. A. Edgar, Research in Coccidiosis, McDougald et al, eds., University of Georgia, p. 617 (1986)].

Another approach to the development of a live vaccine includes the administering of attenuated parasite strains. Selection for early oocyst development or precociousness results in strains having abbreviated asexual development, and reduced pathogenicity [See, Shirley et al, Avian Path., 13:629 (1986); Shirley et al, Res. Vet. Sci., 44:25 (1988); and European Patent No. 0256878-A2]. Serial passaging of Eimeria species in chicken embryos also results in strains of reduced pathogenicity [Long, J. Comp. Path., 82:429 (1972); and Long, J. Comp. Path., 82:439 (1972)].

Both attenuation practices have been used in combination with a "trickle dose" method of administration to achieve effective immunity [Johnson et al, "Research in Coccidiosis", McDougald et al, eds., University of Georgia, pp. 634-641 (1986)]. Although this method has been shown to be useful for vaccination, it requires introduction and maintenance of live parasites in a poultry operation that presents an inherent risk of reversion to pathogenicity.

5

While active infection generates a protective immune response, effective immunisation with killed parasitic stages or structural antigens is less clear. Early studies indicated that antigen extracts from dead parasites were not immunogenic [Long et al, *Exp. Parasitol.*, 16:1 (1965); Rose et al, "Vaccines Against Parasites", Taylor and Muller, eds., Blackwell Scientific Publications, Oxford, pp. 57-74 (1980)].

In contrast, European Patent Application No.

0157443 describes an extract produced from sporulated *E. tenella* oocysts, which when injected intramuscularly, protected chickens against homologous parasite challenge. A similar extract produced from *E. acervulina* oocysts is described in U. S. Patent No. 4,724,145 which elicits a protective response to challenge with that parasite, as well as *E. maxima* and *E. tenella*. An excysted extract of *E. tenella* sporozoites in an aqueous suspension for subcutaneous administration is described in U. S. Patent 4,808,404.

European Patent Application No. 0135712

describes solubilised *E. tenella* sporozoite antigens as effective immunogens; while European Patent Application No. 0135073 refers to the use of antigens from solubilised *E. tenella* merozoites as immunogens.

6

European Patent Application No. 0291173 describes sporulated *E. tenella* extracts for injection into the egg of the bird prior to hatching to induce immunity. U. S. Patent 4,863,731 describes the use of an aqueous concentrate of viable sporulated oocysts from at least one species of coccidia as a feed additive.

In addition, antigen extracts from gametocytes of *E. maxima* are being examined for potential immunogenicity [See, e.g., European Patents No. 0256514 and 0256536]. Although varied degrees of immunity have

been demonstrated with the above preparations, their preparation is highly labor intensive and manufacturing practices are difficult on a large scale.

Recent and more practical approaches to vaccine development involve the production and characterization of genetically engineered antigens [Binger et al, *N. Engl. J. Med.*, 308:144 (1986); Brothers et al, *Mol. Biochem. Parasitol.*, 28:235 (1988); Dunforth et al, *Avian Dis.*, 30:37 (1986); Jenkins et al, *Exp. Parasitol.*, 66:96 (1988); European Patent Application No. 0164176; European Patent Application No. 0317589 and Australian Patent Application No. 65867/86]. These procedures require the isolation of mRNA from sporozoites or merozoites, the production of a cDNA library, screening of the cDNA

library with an appropriate antibody, and the subsequent cloning into an expression vector. The resultant cloned antigens can then be produced in large quantities in microbial fermenters.

Few immunogenicity studies have been reported to date, but suggest partial protection is elicited by these antigens [Danforth and Augustine, supra; Jenkins et al; supra]. Overall, these cloned structural proteins induce incomplete protection at best and their immunizing capability depends in part on host genetics [Clare, Infect. Immunol., 57:701 (1989)].

Finally, passive immunisations with monoclonal antibodies produced against *E. tenella* sporozoites [U. S. Patent No. 4,710,377] and active immunisations with anti-idiotypic monoclonal antibodies [European Patent No. 0241139] derived from *E. tenella* sporozoites are being investigated.

The advancement of knowledge on host/

(protozoan) parasite interactions has been hampered by the lack of adequate *in vitro* cell culture systems in which to maintain parasites. Both mammalian and avian coccidia are very difficult to grow *in vitro*, with the exception of *Toxoplasma gondii*, which grows well in a variety of primary cultures and established cell lines [D. J. Doran, in "The Biology of the Coccidia", pp. 253-

257 (1982)].

In vitro propagation of *Eimeria* has to date been limited. The entire prepatent coccidia development from sporozoite to oocyst, has only been obtained with *E. tenella*, and only in primary avian kidney cells [Doran et al, J. Protozool., 20:658 (1973)]. However, the primary chicken kidney epithelial cell system is not compatible with manufacturing protocols and has limitations for use as a research assay system.

Only one established cell line, Madin Darby Bovine Kidney (MDBK) has been reported to support *Eimerian* growth *in vitro*, but the coccidia develops only through one generation of asexual development [D. M. Schmatz, Adv. Cell Culture, 3:241 (1987)].

Oocysts have been obtained from avian *E. acervulina* [M. Naciri-Bontemps, Ann. Rech. Vet., 7:223 (1976)] and *E. meleagridis* [Augustin et al, J. Protozool., 25:82 (1978)] as well as the bovine *E. bovis* [Speer et al, J. Parasitenkd., (1973)] when initial host-derived macropoites have been used as the inoculum.

To date, no established cell line has been reported to support *Eimerian* growth beyond the first generation of asexual development. There remains a need in the field of prophylactic and therapeutic treatment of various avian pathogenic infections for an established cell line capable of propagating *in vitro* components of *Eimeria* species, to provide safe and effective vaccines against these pathogens, including coccidia.

9

Summary of the Invention

As one aspect, the present invention provides a novel continuous cell line, SB-CEV-1/P, which is capable of propagating avian coccidia. Also described are clones derived from this cell line.

Also part of this aspect of the invention are three additional cell lines propagated from the aforementioned parental cell line. These cell lines are referred to as SB-CEV-1/77, SB-CEV-1/67, and SB-CEV-1/82. Clones, or sub-clones, derived from these cell lines are also encompassed by this invention.

As another aspect, the present invention provides the above cell lines persistently infected with an avian parasite, particularly a Coccidial parasite.

A further aspect of the present invention involves a novel method of vaccine development in which coccidia antigens are produced at various stages of asexual or sexual development by culturing one of the infected cell lines and harvesting cell culture components for use in vaccine compositions.

Yet another aspect of the present invention is a multicomponent vaccine comprising selected pathogenic antigen compositions from various avian coccidia pathogens produced through use of the cell lines described herein.

10

Still a further aspect of the present invention is a vaccine for coccidiosis capable of inducing host protection against infection in poultry containing one or more of the vaccine compositions described above in association with suitable carriers and adjuvants.

Still a further aspect of this invention is a novel method for vaccinating poultry against infection by parasites causing coccidiosis involving administering to an animal an effective dose of the above-described vaccine compositions.

Also involved in this invention is a method for producing a recombinant antigen by transfecting the cell line with a recombinant DNA molecule encoding an exogenous protein under control of a suitable expression control sequence; and culturing the stably transfected cell line under suitable culture conditions to produce the recombinant antigen.

Another aspect of this invention provides a method of drug screening for agents which destroy or inhibit the growth of the selected intracellular parasites comprising exposing the infected cell line of this invention to a selected anti-infective agent, and examining any effects on the pathogen.

Other aspects and advantages of the present invention are described further in the following detailed description of preferred embodiments of the present invention.

Detailed Description of the Invention

The present invention provides methods and compositions for prophylactic vaccination of Aves against infection by avian pathogens and parasites, particularly for the treatment and control of coccidia in poultry. "Poultry" is defined herein to include birds of the order Galliformes, such as the ordinary domestic fowl or chicken (*Gallus domesticus*), turkeys (*Meleagris*), pheasants (*Phasianus*), partridges (*Pedrix*), grouse (*Lagopus*), guinea fowl (*Numida*) and peacocks (*Pavo*), and also birds of the order Anseriformes, such as ducks (*Anas*) and geese (*Anser*).

This invention provides a novel continuous cell line SB-CSV-1/P, described in detail in Example 1 below. This cell line has 42 chromosomes per cell, and is reverse transcriptase negative. The cell line is characterised as containing only a low incidence of non-infectious viral particles (type A) associated with the endoplasmic reticulum. The cell line is also negative for endogenous mammalian pathogens, and has no indication of avian leukosis virus. Further the cell line has no contamination with mycoplasma, bacteria or fungi. Thus the cell line is free of mammalian and avian viruses.

This cell line also has functional characteristics which associate it with avian background. For example, this cell line replicates at 41°C, characteristic of avian cells and it has unique nutritional requirements for maintenance *in vitro*. Further, the novel cell line of this invention is the only existing continuous cell line capable of replicating the prepatent life cycle (i.e., that period between infection and the detection of the parasite in the body) of the avian coccidia, *Eimeria*, at high levels.

The SB-CSV-1 cell line of this invention has been selected for the production of vaccine antigens, particularly avian coccidia. The cell line also provides substrates for use in the growth of genetically engineered vectors expressing recombinant DNA derived from foreign genes.

Several cell populations have been cloned from this parent cell line. These clones have distinct characteristics for propagation and maintenance of the avian parasite. Further these cloned cell populations, SB-CSV-1/P7, SB-CSV-1/57, and SB-CSV-1/A2 have a high incidence of multinucleated giant cells. The appearance of distinct clones from the parent cell line is also indicative of a multicellular origin, e.g., possible

13

aberrant growth in the chicken viscera used as the origin of the parent cell line. These cloned "progeny" cell lines, however, are also continuous cell lines capable of replicating the prepatent life cycle of the avian coccidia, *Eimeria*, at high levels. These cell lines are believed to share the same characteristics as the parental strain, and have also shown the ability to propagate coccidia. This invention, therefore, also encompasses other cell lines which are subcloned from, or otherwise derived from, SB-CEV-1/P or from the specifically identified clones of that parent cell line. Such additional progeny clones are anticipated to share significant characteristics of the parent cell line.

Thus the sub-clones may be substituted for the parent cell line wherever SB-CEV-1 or SB-CEV-1/P is specifically mentioned throughout this specification. Also, wherever in the following description, a cell line is referred to in the singular, the term "the cell line" or "the SB-CEV-1 cell line", is meant to include SB-CEV-1/P, its subclones SB-CEV-1/F7, SB-CEV-1/G7, or SB-CEV-1/A2, or any other subclones of any of these specifically identified cell lines.

The parent cell line and the subclones thereof of the present invention may be employed to support the *in vitro* development of avian *Eimeria* species. While the disclosure below refers specifically to methods and

14

vaccine compositions for *E. tenella* infections, it should be understood that other avian parasite pathogens, including viruses, as well as other animal species protozoans, may be produced using a cell line of this invention in analogous procedures. Thus the cell line is capable of providing an expression system for a variety of pathogenic antigens and other proteins for use in research, characterization and the production of vaccine components. In addition, as the only existing continuous cell line that replicates the prepatent life cycle of avian *Eimeria*, the cell offers a unique substrate to study enzymatic and genetic characteristics of a parasite permissive cell line.

The cell line of this invention also provides a means for production of recombinant avian vaccine components, such as subunit antigens derived from reovirus, coronavirus, herpesvirus, parv- and orthomyxoviruses. The cell line may be transfected by a recombinant DNA molecule or expression vector encoding a selected pathogen protein or peptide under the control of conventional regulatory control sequences, and cultured. The recombinant protein may then be expressed by the cultured SB-CEV-1 cell line or its progeny.

15

The novel cell line also provides a substrate for replication of other *Eimeria* species. This continuous cell line of the invention may also be utilised to isolate and characterise independent stage specific components of intracellular parasitic stages. Specifically, this cell line provides the only source of readily available parasite DNA, RNA, and protein from intracellular structures. Further, this cell line may be used to grow other desired, selected pathogens.

The SB-CFV-1 cells of the present invention permit development of the chicken species *E. tenella* and *E. nasutrix*, as well as development of the turkey coccidia, *E. adenocides* and *E. meleagridis*. It is expected that the cell line will also permit the development of other species, e.g., *E. acervulina* and *E. maxima*.

The presently preferred culture conditions for growth of the cell line include culturing the cell line in Medium 199 [Irvine Scientific] and 5% fetal bovine serum (FBS) (or equivalent such as OptiMem and 1% FBS) under incubation conditions of 5% CO₂ and 40.5°C. The cells grow more slowly at 37°C rarely reaching confluency and require at least 10% serum. Other culturing conditions, including media formulations with regard to specific nutrients, oxygen tension and reduced serum, may be employed for growth of these cells, and may be selected and optimised by one of skill in the art.

16

The novel cell line of this invention, SB-CFV-1/P, was deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland on July 3, 1990 under ATCC No. CRL10497. The development of this cell line is described in detail in Example 1 below. The progeny cell line SB-CFV-1/P7 was similarly deposited on July 3, 1990 under ATCC No. CRL10495. The progeny cell line SB-CFV-1/G7 was deposited on July 3, 1990 under ATCC No. CRL10496. These deposits comply with the requirements of the United States Patent and Trademark Office for microorganism deposits made for patent purposes, and will be made to comply with the requirements of the Budapest Treaty at the time of foreign filing.

The present invention further provides a variety of vaccine components and compositions prepared by the use of the cell line of this invention. A particularly desirable embodiment of this invention is a vaccine composition derived from *Eimeria* parasites. This vaccine composition may contain whole cell extract (live or inactivated) from the above-described cell lines infected with a selected pathogen, or subfractions thereof. These vaccine compositions may also contain modified cellular or parasitic antigens, produced by modifying the culture conditions of the infected cell line.

International Application No. PCT/

/

MICROORGANISMS	
Original filed in connection with the international application referred to in page 15, of the description.	
A. IDENTIFICATION OF DEPOSIT	
Further deposits are described on an additional sheet.	
Name of depositary institution:	
Medicon Type Culture Collection	
Address of depositary institution (including postal code and country):	
12301 Parklawn Drive Rockville, Maryland 20852 USA	
Date of deposit:	Accession Number:
3 July 1990	CEL 10497
B. ADDITIONAL INDICATIONS (Leave blank if not applicable). This information is contained on 2 separate sheets. <input type="checkbox"/>	
In respect of those designations in which a European patent is sought, a sample of the deposited micro-organisms will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)	
C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (If no indication is set for all designated States)	
ALL	
D. SEPARATE FURNISHING OF INDICATIONS (Leave blank if not applicable)	
The indication filed below will be submitted to the International Bureau later. (Specify the period within of the indication is to be submitted to the depositary institution.)	
<input checked="" type="checkbox"/> The sheet was received with the international application when filed as required by the depositary institution. (Indicate date) <i>3 July 1990</i>	
<input type="checkbox"/> The date of receipt (from the applicant) by the depositary institution is:	

International Application No. PCT/

/

MICROORGANISMS	
Original filed in connection with the international application referred to in page 15, of the description.	
A. IDENTIFICATION OF DEPOSIT	
Further deposits are described on an additional sheet.	
Name of depositary institution:	
Medicon Type Culture Collection	
Address of depositary institution (including postal code and country):	
12301 Parklawn Drive Rockville, Maryland 20852 USA	
Date of deposit:	Accession Number:
3 July 1990	CEL 10495
B. ADDITIONAL INDICATIONS (Leave blank if not applicable). This information is contained on 2 separate sheets. <input type="checkbox"/>	
In respect of those designations in which a European patent is sought, a sample of the deposited micro-organisms will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)	
C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (If no indication is set for all designated States)	
ALL	
D. SEPARATE FURNISHING OF INDICATIONS (Leave blank if not applicable)	
The indication filed below will be submitted to the International Bureau later. (Specify the period within of the indication is to be submitted to the depositary institution.)	
<input checked="" type="checkbox"/> The sheet was received with the international application when filed as required by the depositary institution. (Indicate date) <i>3 July 1990</i>	
<input type="checkbox"/> The date of receipt (from the applicant) by the depositary institution is:	

20

In one embodiment, vaccine compositions for use in vaccines to avian oocidiosis are developed by infecting a cell line of this invention with a selected parasite, preferably an *Eimeria* parasite, e.g., *E. tenella*. Infection of the cells is monitored by use of an *in vitro* enzyme-linked immunosorbent assay (ELISA) employing conventionally developed monoclonal or polyclonal antibodies to various life cycle stages of the parasite. The infection may also be measured by a radiolabelled uracil uptake assay. Both the ELISA and uptake assays are described in detail in Example 2 below.

Approximately 72 hours post-infection the cells and medium or extracellular secretions are harvested by collecting cells and/or culture fluids. As an optional step, if necessary, the culture fluids may be inactivated using conventional techniques, such as by sequential freeze/thaw cycles or by the addition of filtration, denaturing or crosslinking agents such as β -propiolactone, formaldehyde or glutaraldehyde.

Various portions of this infected cell culture preparation may be employed in vaccine compositions:

- 1) the whole preparation without subfractionation;
- 2) a modified preparation affected by changes in the culture media and conditions (e.g. the omission of serum

- 9 -

International Application No: PCT/

MICROORGANISMS

Optimal sheet to be completed with the observations referred to in part 15 of the description 1

A. IDENTIFICATION OF DEPOSIT

Further deposits are identified as an additional sheet 21.

Name of depositing institution

American Type Culture Collection

Address of depositing institution (including postal code and country)

12301 Parklawn Drive
Rockville, Maryland 20852 USA

Date of deposit

3 July 1990

Accession number

CRL 10496

B. ADDITIONAL INDICATIONS: (When blank it is not applicable. This information is contained on a separate attached sheet) ☐

In respect of those designations in which a European patent is sought, a sample of the deposited micro-organisms will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample. (Rule 28(4) EPC)

C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE: (If the indications are not for all designated States)

All

D. SEPARATE FURNISHING OF INDICATIONS: (When blank it is not applicable)

The indications must be submitted to the International Bureau (Specify the general name of the International Bureau of Intellectual Property)

E. This sheet was received with the international application when filed (to be checked by the receiving Office)

(Authorised Officer)

☐ The date of receipt (from the applicant) by the International Bureau is

21

during critical growth periods, pH or ion changes);

3) subtraction to produce cell associated soluble components; and 4) subtraction and modified vaccine components.

5 One embodiment of a vaccine composition or component according to this invention is prepared by disrupting the infected cells of the above-described culture by scraping. The resulting disrupted cell composition is used for a vaccine preparation without further desiccation or hydration.

10 As another vaccine component of this invention the above-described vaccine component may be modified by altering the serum concentration or components and other nutritional additives, in the medium employed to culture the parasite-infected cell line of this invention. For example, early stages of the parasite may be arrested by culturing the infected cell line in minimal essential medium, MEM. Alternatively, by substituting chemically defined media, the cell line will permit later stages of parasite development to be employed in the vaccine.

15 Additional nutritional changes to the medium which may affect parasite development and modify the antigenic proteins produced in the cell line of this invention involve the addition or subtraction from the media of one or more of biotin, choline chloride, insulin, or non-essential amino acids.

22

A modified vaccine component may also be produced in the infected cell line by the application of classical mutagenic techniques, e.g., the addition of alkylating agents, chelating agents, dimerizing agents or outside treatment of the cell line by ultraviolet light during the culture of the infected cell line. These agents may genetically modify the cell and provide it with an altered capacity to produce an abnormal parasite. Alternatively, depending on the stage of development of the parasite within the cell when it is first contacted with the mutagenic agent, the parasite itself may be directly mutagenized for the production of a preferred vaccine component.

10 Still another embodiment of a vaccine composition for use in prophylactic treatment of aves, particularly poultry, against Coccidia is prepared by the methods above using subfractions formed by the disrupted cells and the medium from the cell culture. These fractions are obtained by first separating the media from cell fractions, e.g., by centrifugation, size, molecular weight, charge, or various conventional biochemical means. These fractions are then employed as vaccine compositions which may be presented to birds. For example, one fraction of the above-described cell culture

23

is obtained by centrifuging the medium containing the disrupted cells. The medium is removed, and the remaining material pelleted to obtain the cellular components. This pellet is resuspended in fresh tissue culture media. In addition, the supernatant fraction may also be utilized as a vaccine component.

One or more of the above described vaccine components can be admixed or adsorbed with a conventional adjuvant or administered without an adjuvant. The adjuvant is used as a non-specific irritant to attract leukocytes or enhance an immune response. Such adjuvants include, among others, oil and water, aluminum hydroxide, muramyl dipeptide, killed Bordetella and saponins, such as Quil A. Presently, the preferred adjuvant is Amphigen [Hydronics Inc.; U. S. Patent No. 5,084,269].

A preferred vaccine dosage is between approximately 0.05 μg - 100 μg of parasite protein. Other appropriate therapeutically effective doses can be determined readily by those of skill in the art based on the above immunogenic amounts, the condition being treated and the physiological characteristics of the animal. Accordingly, a pharmaceutical preparation provides a unit dosage of between 0.1 to 2 mls of a

24

sterile preparation of an immunogenic amount of the active vaccine components, or a combination thereof. In the presence of additional active agents, these unit dosages can be readily adjusted by those of skill in the art.

A desirable dosage involves administration of 1 to 2 doses of desired vaccine composition, where the antigenic content of each fraction is desirably as stated above. The mode of administration of the vaccines of the invention may be any suitable route which delivers the vaccine to the host. However, the vaccine is preferably administered subcutaneously. However, the vaccine may also be added to feed or water for ingestion in the form of a suspension. Other modes of administration may also be employed, where desired, such as intradermally, intravenously, or intramuscularly.

It will be understood, however, that the specific dose level, mode and timing of administration for any particular animal will depend upon a variety of factors including the age, general health, and diet of the animal; the species of the animal; synergistic effects with any other drugs being administered; and the degree of protection being sought. Of course, the administration can be repeated at suitable intervals if necessary or desirable.

25

In preliminary tests of these vaccines, bird performance is enhanced. Preliminary results show that the above-described vaccine, which was formed by simply decanting conditioned media or disrupting the SB-CEV-1 cells, and harvesting by centrifugation the cell fluids, enhances bird performance during challenge. Additionally the subinfection vaccine described above also has shown efficacy in an *in vivo* assay. The *in vivo* tests are conducted as follows. Chicks two weeks of age are immunised subcutaneously with 1 ml of culture media harvest. Two weeks later, the chicks are challenged with 10,000 oocysts of *E. tenella*. For the next 6 days, the chickens are monitored for aspects such as weight gain and feed efficiency. Intestinal lesions are thereafter screened and subjects are scored on this basis. This assay is described in more detail in Example 4 below.

In addition to the use of the cell lines of this invention for the development of vaccines, these cell lines may also be used in methods for screening anti-parasitic agents in the development of new anti-coccidia drugs. For example, cultures of infected cells may be conventionally labeled, e.g., with a radioactive molecule. The selected drug for testing may then be incorporated into the cell cultures. The cell culture may then be harvested at discrete intervals post infection, and label incorporation of the radioactive

26

precursor may be determined by harvesting and processing for scintillation counting. An example of such drug screening employing alpha-amanitin as the test drug is described in detail in Example 5 below. If a drug is effective at a particular dose or time of administration, the incorporation of counts (parasite material) should be halted. If no inhibition of label incorporation is observed, the drug is ineffective in controlling the parasite infection *in vivo*.

Other conventional drug screening modes known to those of skill in the art may also be employed using the cell lines of this invention.

The following examples illustratively describe the production of the novel continuous cell lines of this invention. These examples are for illustration only and do not limit the scope of the present invention.

Example 1 - Isolation of Parental Cell Line, SB-CEV-1P, and Clones SB-CEV-1V7 and SB-CEV-1V7

SB-CEV-1 cells were isolated from an abnormal tissue mass (approximately 1 cm X 2 cm) associated with the visceral connective tissue of one 20 day old SPAPAS [COPAL-24] chicken embryo. The tissue was aseptically removed and rinsed in Hank's Basic Salt Solution (HBSS)

containing 1% Fungi-Bact Solution [Irvine Scientific, Irvine, CA]. The tissue was minced with scissors, then enzymatically dissociated using 0.25% trypsin (1:250) in HBSS. The dissociated cell suspension was collected in a

5 50 ml centrifuge tube containing 0.5 ml fetal bovine serum to inactivate the trypsin and centrifuged at 700 g for 10 minutes.

The cells were resuspended in 5 ml Weymouth's MAB87/3 media [Irvine Scientific] supplemented with 8 mg/1 bovine insulin [Collaborative Research, Inc.,

10 Bedford, MA], 12 ml/1 200 mM L-glutamine and 1% Fungi-Bact Solution [Irvine]. This 5 ml volume was pipetted into a 25 cm² Corning tissue culture flask and incubated at 40.5°C in 5% CO₂. After 24 hours of incubation, the media was changed. This primary culture contained numerous explants with centers of epithelial-like cells and radiating fibroblasts.

After 72 hours, the near-confluent culture was washed once with Ca⁺⁺/Mg⁺⁺-free phosphate buffered saline (PBS) then treated with 0.02% ethylene diamine

20 tetraacetic acid (EDTA) in HBSS to dissociate the cells. The resulting cell suspension was decanted, the cells were collected by centrifugation and resuspended in the MAB87/3 media formulation used previously. This culture was then split 1:10, creating passage-1 (P1) by plating cells in seven 25 cm² culture flasks and two 60 mm² petri dishes. Cultures were incubated as before.

Media was changed on actively growing cultures at 72 hours omitting fetal bovine serum (FBS). The media in one flask was replaced with Medium 199 [Irvine

Scientific] supplemented with 10% FBS. After an additional 48 hour incubation, the culture containing

5 Medium 199 showed actively growing cells, while the MAB87/3 cultures were static. Returning serum to these cultures up to 10% did not promote cell growth to the level observed using Medium 199. Therefore, all subculturing was done, hereafter, in Medium 199 plus 10% FBS.

Further subculturing was done (Passage-2 to Passage-11) when flasks reached confluency. With increasing passage number, cells grew more slowly, became fibroblastoid and highly vacuolated and released debris into the media. Additional media formulations (EMEM + 10% FBS; RPMI 1640 + 10% FBS; DMEM/Ham's F-12 + 5% FBS) were tested on these cells to forestall or counteract

this pending senescence. However, cells showed the least detraciation in Medium 199. Cells from several passages (P4, P5, P6, P7, P9, P10) were frozen down in liquid nitrogen. These cells appeared to reach crisis at P11-13 and died.

One 75 cm² flask of P11 cells containing a very few isolated foci of cells was repeatedly fed with Medium 199 and 10% FBS for 58 days after its last subculturing.

29

At this point, fibroblast-like cells began to grow outward from these foci. After an additional 15 days, cells in this 2-75 flask reached confluency and were split 1:2 creating P12.

5 Subculturing has continued to the present in Medium 199 (Gibco Laboratories, Grand Island, NY), 3.43 ml/l of 200 mM L-glutamine and 1% Antibiotic-Antimycotic (Gibco Laboratories) using the passage criterion of splitting 1:20 every 7 days. The cells have lost all epithelial characteristics and are distinctly fibroblast-like in morphology. Other media formulations used successfully since crisis include Weymouth's MBM7/3 and 5% FBS, Dulbecco's MEM (Gibco Laboratories) and 5% FBS and MEM with Earle's salts (Gibco Laboratories) and 5% FBS. The FBS requirement has been reduced to 5% for SB-CEV-1 cells of passage 24 which were subjected to subcloning by dilution using single-cell isolation in 96 well microculture plates. This technique produced 25 clones from the parental cell line SB-CEV-1/P in unconditioned Medium 199 with 5% FBS. Of these clones, two, designated SB-CEV-1/P7 and SB-CEV-1/P7', showed an exceptional capacity to support asexual development of *E. tenella*.

25 These two clones along with the parental line, SB-CEV-1/P have been deposited with the ATCC as identified above. Passage No. 10 was deposited for both clones and passage No. 20 for the parental line.

30

Freezing has not had any deleterious effect on cell performance as several frozen samples have been restored successfully. Standard biologic quality control was satisfactory from P13 of the parent line. In addition, the parent line shows a karyotype of approximately 42 chromosomes, is reverse transcriptase negative, does not express avian retroviruses (e.g. avian leukosis), does not express other endogenous pathogens (mammalian or avian), is tumorigenic in nu/nu mice, and shows no bacterial, fungal or mycoplasma contamination. A low incidence of A-type viral particles associated with the endoplasmic reticulum was resolved by transmission electron microscopy. The parent line as well as both clones showed isoenzyme focusing profiles similar to BHK-21 cells [National Veterinary Services Laboratory] and dissimilar to SL29 cells (a transformed chicken fibroblast line) [ATCC No. CRL1590] for the enzymes lactate dehydrogenase, malate dehydrogenase, nucleoside phosphoribylase, peptidase A and phosphoglucomutase. In contrast, both clones and the parent SB-CEV-1 line are morphologically distinct from BHK-21 and ACC-111 cells. In addition, the SB-CEV-1 cell lines show a high incidence of multinucleated giant cells. Most importantly, the SB-CEV-1 cells produce high levels of parasite material from different stages of the *Eimeria* prepatent life cycle.

25

31

Example 2 - Assays to Monitor Parasite Development in the Cell Line

A. The direct sporozoite-based enzyme linked immunosorbent assay for detection of oocoidia proteins (SPZELISA) involves the adherence of antigen (e.g., supernatants from uninfected or infected Y7 cells or disrupted sporozoites (SPZ) or macozoites) in twofold serial dilutions to the well of a 96-well tray.

Antibodies which recognize SPZ antigens bind to the antigen in a dose related response. After the primary antibody is bound, a second antibody produced in goats against rabbit IgG which is also biotinylated is added. Again, this anti-rabbit antibody will bind to the rabbit #15, 16 anti-SPZ antibody previously bound to antigen in the wells. The anti-SPZ antibodies were produced as follows. Purified sporozoites (described below) for E. tanella were suspended in serum free media at a concentration of 2.5×10^6 sporozoite per ml. An equal volume of Freund's Complete Adjuvant was added mixed and 0.5 ml was inoculated subcutaneously at 2-4 sites on the back of 6 kg New Zealand white rabbits (mixed sexes).

Booster inoculations were given in a similar manner using Incomplete Freund's Adjuvant at 2 to 4 week intervals (3 inoculations minimum). Blood was collected in serum vacutainers (Becton-Dickenson) two weeks after third

32

inoculation. The serum was allowed to clot at room temperature for 1 hour and then was centrifuged at 2000 rpm for 10 minutes to pellet the clot. The serum was removed, aliquoted into 1.5 ml per tube and stored at -20°C. After the secondary antibody is bound, an enzyme-labelled streptavidin which binds to biotin is added. Substrate is incubated and the enzyme linked to streptavidin bound to the well will convert the substrate to a visible form. The amount of color measured is proportional to the amount of antigen cross-reactive to SPZ proteins in the test supernatant. Included on the plate are samples containing antigens from uninfected supernatants as a negative control as well as sonically disrupted SPZ. This sporozoite material serves as a positive control and is used to generate a standard curve against which parasite antigens in infected supernatants are measured. In this manner, parasite-specific material in infected cell supernates can be quantitatively assessed and compared.

Approximately fifty 3-4 week old birds are each infected orally with 100,000 E. tanella oocysts. Cecal pouches are harvested at approximately 7.5 days and lumen contents subjected to pepsin digestion. Oocysts then undergo sporulation in 2.5% potassium dichromate for 3-4

33

days and are sterilized by chlorine bleach. The sterilized oocysts are stored at 4°C in Medium 199 + 2X antibiotic. Generally, fifty birds yield approximately 5 x 10⁶ oocysts. This protocol is repeated every 3-4 weeks to maintain virulence.

Cell culture antigen for the assay is produced according to the following modified excystation procedure. The sporozoysts are purified by breaking 10 ml oocysts (at 3 x 10⁶/ml) with 5 ml 0.5 µm glass beads in a small chamber bead beater and separating the debris using

0.75 M sucrose in PBS followed by centrifugation using 50% isotonic Percoll. Using a solution consisting of 4% (w/v) tauradeoxycholic acid, 0.25% (w/v) trypsin, HBSS, and adjusting to pH 8.0 with bicarbonate, SPZ excystation is performed by incubating this mixture with the purified sporozoysts at 40.5°C, 60-90 minutes with vortexing at approximately 15 minute intervals. The SPZ are then collected using 60% isotonic Percoll, the pellet is resuspended in serum-free media and counted. Generally, 3 x 10⁶ oocysts yields approximately 7.2 x 10⁶ SPZ (30%). The SPZ are sonicated and stored at -20°C as a standard source of antigen for the assay.

The antigen seeding is performed as follows. 200 µl of antigen prepared in 10 mM borate buffer, pH 9.0, is added to the top wells of a 96 well Nunc Immuno plate. All remaining wells contain 100 µl of the borate

34

buffer alone. Serial 2-fold dilutions are made in rows B-G. Row H contains only buffer and is used as a negative control. The wells are covered with parafilm and incubated overnight at 4°C. The SPZ control is loaded at 10 ng in the top row of wells. Antigen without 1% PBS is loaded at 100 ng and antigen + 1% PBS (Gibco) is loaded at 1000 ng. Supernatant antigens from uninfected P7 cells are included as a negative control in each assay. Supernatants harvested at 72 hours from a designated infected passage of P7 cells are also included on each plate as an internal standard. The 72 hours supernatant is first quantitated by the SPZELISA and then its relative value is compared to the SPZ control is used to monitor and adjust for assay-to-assay variability.

Next, supernatants are washed 3X with PBS + 0.05% Tween-20 (PBS-T) and blocked by adding 200 µl of 5% skim milk (Difco) in PBS-T to each well. Wells are incubated 1 hour at 37°C covered with plastic wrap, and are washed again 3X with PBS-T. The primary antibody is then added. 100 µl of rabbit anti-SPZ antibodies #15, 16 diluted to 1:20,000 in 0.5% BSA in PBS-T is added per well and the plates are incubated 1 hour at 37°C covered with plastic wrap. The plates are washed again 3X with PBS-T. Following this, the conjugated antibody, 100 µl of 1:2000 dilution of biotin-labeled goat anti-rabbit IgG

(KP) in 2% skim milk in PBS-T, is added per well. The plates are again incubated 1 hour at 37°C and then washed 3X with PBS-T. Following this, 100 μ l of 1:1500 dilution of peroxidase-labeled streptavidin (Kirkegaard Perry) in 2% skim milk in PBS-T is added per well. The plates are then incubated 1 hour at 37°C in the dark and washed 3X with PBS-T. TBH-Peroxidase [Kirkegaard Perry] is mixed in a 1:1 ratio with H_2O_2 and 100 μ l of substrate per well is added. The plates are then incubated 15 to 30 minutes at 37°C in the dark. At the end of the incubation time, 100 μ l of 1 M HCl per well is added to stop the reaction. Readings are taken at 450 nm on the Vmax.

B. Another assay employed to monitor parasite development in the cells takes advantage of the parasite's, but not the host's, ability to incorporate radiolabelled uracil into its RNA [D. M. Schmatz et al., J. Protozool., 23:109-114 (1986)]. Briefly, cultures of cells in microtiter plates are seeded at 1×10^5 cells/ml, 0.1 ml/well, 24 hours prior to infection with *E. tanalla* at 1×10^5 sporozoites per well. The sporozoites are incubated with the cells for 4 hours at 40.5°C and then removed by washing with serum-free medium. The cells are then overlaid with medium and serum and incubated for 24 hours. At 24 hours post-infection, the cells are washed and then refed with medium containing [³H]-uracil. Label is incorporated over a 24 hour period and then the cells

are collected onto filters using a cell harvester (Cambridge Technology, Inc.). Radioactivity on the filters is determined in a Beckman LS 3801 liquid scintillation counter after the addition of aqueous scintillation cocktail (Beckman Ready Safe). Background counts and radiolabel incorporated into uninfected cells are also measured.

Example 3 - Avian Vaccines

A. One vaccine formulation is prepared from a SB-CSV-1/P host cell clone seeded at a rate of 1.0×10^5 cells/ml in a T-150 flask containing 30 ml of either Medium 199 containing 5% FBS (Irvine Scientific) or OptiMEM containing 1% FBS. *E. tanalla* sporozoites, excysted by conventional techniques known to those skilled in the art, are used as inoculum 24 hours later at a rate of 1×10^5 /ml. The sporozoites are left to invade for 2 hours, after which non-invaded sporozoites are removed by gentle washing. Fresh media is added to each flask. At 24 hour intervals post infection, the culture media is collected, centrifuged at 3000 x g for 30 min, and adjuvanted with 5% Amphigen. This formulation (designated 24 hour supernate, 48 hour supernate and 72 hour supernate, etc.) is stored at 4°C until use.

37

B. An alternative formulation utilizes the remaining cells from the above-described vaccine. A volume of 30 ml fresh media, Medium 199 or OptiMEM, is added to the T-150 flask, and the cells are scraped into suspension. This suspension is collected, subjected to a freeze/thaw cycle, and adjuvanted with 5% Amphigen. This formulation is stored at 4°C until use.

C. A still alternative formulation utilizes the entire infected culture from the above-described vaccine, unfractionated. Upon harvest, the infected cells are scraped into suspension. This suspension is collected, subjected to a freeze/thaw cycle, and adjuvanted with 5% Amphigen. This formulation is stored at 4°C.

15 Example 4 - Immunogenicity Data

A. Broiler Immunogenicity Study #1

A study was conducted to screen *Escherichia coli* culture-derived antigens for immunogenicity in commercial broilers comparing Amphigen and Freund's Complete Adjuvant (FCA) as adjuvants for the primary immunization.

Three hundred 4 day old straight run commercial broiler chicks were divided among twenty groups (15 birds per group and wing-banded) as follows. PSP refers to parasite-specific protein which is quantitated using the direct SPKRTSA described in Example 2 above.

38

GROUP TREATMENT-ANTIGEN		PSP	GROUP TREATMENT-FCA		PSP
1A	Unchallenged control	0 µg/ml	1B	Unchallenged control	0 µg/ml
2A	Challenged control	0	2B	Challenged control	0
3A	24h antigen	0.70	3B	24h antigen	0.35
4A	48h antigen	1.40	4B	48h antigen	0.70
5A	72h antigen	1.40	5B	72h antigen	0.70
6A	24/48h (1:1)	1.10	6B	24/48h (1:1)	0.60
7A	24/48/72h (1:1:1)	1.20	7B	24/48/72h(1:1:1)	0.60
8A	24h primary/48h boost	0.7/1.4	8B	24h primary/48h boost	0.38/0.7
9A	5 X 500 Trickle		9B	5 X 500 Trickle	

Chicks in Groups 1-8 were immunized subcutaneously (sc) at 4 days of age as designated, and boosted orally with the same amount of antigen in 5% Amphigen at 7 days of age. Both control groups received 1 ml inoculations of tissue culture medium (Cibco Medium 199 + 1% FBS) adjuvanted to 5% Amphigen or 1:1 with FCA (SIGMA). Antigen for Groups 3-8 was prepared from host cell clones F7 (P24-31) for the 24 hour antigen and F7 (P24-29) for both 48 hours and 72 hours antigens. Antigens were stored at -20°C until use or subjected to one freeze-thaw cycle.

E. tenella oocysts for groups 9A and 9B were administered orally, 500 oocysts per day for 5 consecutive days (Dilly strain #65 strain, Lilly, CO) [gift from University of New Hampshire (UNH)]. In addition, group 9B birds received a s.c. injection of 50% FCA at 4 days of age.

Groups 2-9 were challenged with 35,000 L.S. #65 *E. tenella* oocysts (number determined by titration) at 21 days of age. At this time, body weights of all chicks were measured, and feed consumption monitored during the prepatent period. Six days post challenge, body weights, feed consumption and cecal lesion scores were measured.

The clinical data from Trial #1 has been

summarised in Tables 1 and 2. All least squares statistical comparisons for weight gain were made between vaccinates the unimmunised/challenge (UI/C) control group. Main effects tested included Treatment, Pens within Treatments, Sex, and a Sex by Treatment interaction. Both Amphigen and FCA data sets were tested separately. For both data sets a significant interaction with treatment permitted analysis across sexes. No sex effect was measured for lesion score. Feed conversion was tested for only treatment effects.

In the following table, UI/UC means

Unimmunized/Unchallenged; and Ag represents antigen.

TABLE 1
Clinical results of Trial #1 - Amphigen

TREATMENT	N	WEIGHT GAIN	FEED CONVERSION	LESION SCORE
UI/UC	13	287	1.8	0
UI/C	13	223	2.1	2.5
24 hour Ag	14	255	1.9	2.9
48 hour Ag	14	223	2.1	2.9
72 hour Ag	15	264#	1.5*	2.8
24/48 hour Ag	14	261#	2.0	2.8
24/48/72 hour	14	262#	2.0	2.6
24->48 hour	15	273*	1.9	2.6
Trickle	6	257	1.8	2.8

*p<0.05

#p<0.1

TABLE 2
Clinical results of Trial #1 FCA

TREATMENT	N	WEIGHT GAIN	FEED CONVERSION	LESION SCORE
UI/UC	15	286	1.8	0
UI/C	15	243	2.0	2.7
24 hour Ag	15	260	1.9	3.0
48 hour Ag	14	233	2.1	2.6
72 hour Ag	15	231	2.6	2.8
24/48 hour Ag	14	253	1.9	2.9
24/48/72 hour	15	196*	2.3	2.9
24->48 hour	15	215	2.2	2.5
Trickle	15	266	1.9	1.5*

*p<0.05

41

Amphigen adjuvanted cell culture antigens

administered sc at 4 days of age and orally at 7 days of age elicited significant ($p < 0.05$) or near significant ($p < 0.1$) weight gain protection to a 35,000 R. typhosa oocyst challenge in battery cages. The regimen of 24 hours antigen s.c. followed by 48 hours antigen orally elicited significant weight gain performance, while gains sustained by the 72 hours antigen and combinations 24/48 hours and 24/48/72 hours approached significance. None of the Amphigen adjuvanted treatments effected a reduction in lesion scores. Only the 72 hours antigen vaccinated group showed a significant enhancement of the feed conversion ratio. The trickle oocyst immunized groups did not test significant for protection.

Cell culture adjuvanted with PCA elicited no significant protection to challenge, measured by weight gain or feed conversion. In fact the group immunized with the 24/48/72 hours antigen combination had significantly lower weight gains than the challenge control group. Only the trickle oocyst group had a significant reduction in lesion scores.

The following conclusions can be drawn from this data. The regimen of 24 hours s.c./48 hours oral vaccine elicited significant weight gain protection to challenge when adjuvanted with Amphigen. The 72 hours antigen and combinations of 24/48 hours and 24/48/72

42

hours antigens, all adjuvanted with Amphigen, also showed indications of protection in terms of weight gain. These findings suggest that each antigen preparation contains either a different composite of antigens or a different ratio of similar antigens.

Weight gain protection was measured in the absence of any reduction in lesion scores, indicating that these parameters are affected by different mechanisms. Weight gain and feed conversion performance may be sustained even in the presence of caecal lesions.

While the 48 hours antigen alone was ineffective, this antigen in combination with the 24 hours and/or 72 hours antigens or administered orally at 7 days may be critical to establishing immunity to challenge. It is assumed that the 72 hours antigen harvest contains a composite of antigens representative of all three time points.

PCA was not successful in potentiating immunogenicity of cell culture antigens. PCA alone may be eliciting a non-specific response to challenge as indicated by the higher challenge control weight gains in the PCA data set.

The importance of the oral dose, its time of administration, and subsequent impact on performance in a floor pen design including a grow-out following challenge is evaluated in the following studies (part B).

B. Broiler Immunogenicity Study #2

The purpose of this study was to screen several

Escherichia coli culture-derived antigens for

immunogenicity in commercial broilers using floor pens,

5 and including a 40 day grow-out.

Two hundred fifty 4 day old male commercial

broiler chicks were divided among ten groups (25 birds

per group and wing-banded) as follows. In the table,

UI/UC/Med means Unimmunized/UnChallenged/Medicated;

10 UI/UC/Unmed means Unimmunized/UnChallenged/UnMedicated;

and UI/C/Unmed means Unimmunized/Challenged/UnMedicated.

GROUP	TREATMENT	PSP Dose
1	UI/UC/Med	0 µg/ml
2	UI/UC/UnMed	0
3	UI/C/UnMed	0
4	24 hours, 4d	2 µg/ml
5	24 hours, 4d/7d	2 µg/ml
6	72 hours, 4d	2 µg/ml
7	72 hours, 4d/7d	2 µg/ml
8	24/48 hours, 4d	2 µg/ml
9	24/48 hours, 4d/7d	2 µg/ml
10	24 hours, 4d	2 µg/ml
	48 hours, 7d	1.6 µg/ml

All chicks were held on wire until 4 days of

25 age. At that time, chicks in Groups 1-10 were immunized

s.c. and placed into clean litter floor pens as

designated. Chicks in Groups 5, 7, 9 and 10 were boosted

orally as designated at 7 days of age. Control groups

received 1 ml inoculations of tissue culture medium

30 (Gibco Medium 199 + 1% FBS) adjuvanted to 5% Amphigen.

In addition, Group 1 was given feed medicated with stenerol, at 3 ppm, throughout the study. Antigen for Groups 4-10 was prepared from host cell clones P7 (P24-24) and adjuvanted with 5% Amphigen.

5 All chicks were fed a starter ration through 27 days of age, and switched to a grower ration for the day 27-40 grow-out. Feed and water were provided ad libitum.

10 All birds in groups 3-10 were challenged with 35,000 (dose determined by titration) L.S. #65 *E. tenella* oocysts at 21 days of age. At this time, body weights of all birds were measured, and feed consumption monitored during the prepatent period.

15 Six days post challenge, body weights and feed consumption were measured. In addition, five birds from each pen were selected randomly for cecal lesion scoring. All remaining birds were switched to a grower ration and continued until 40 days of age. During this time both weight gain and feed consumption were monitored. At day 40, all birds were sacrificed for cecal lesion scoring.

20 The clinical data from Trial #2 has been summarized in Table 3. All least squares statistical comparisons for weight gain were made between the unimmunized/challenge (UI/C) control group and each individual treatment group (not with the medicated control group). No statistics were performed on lesion score or feed date (one observation/group).

45

TABLE 3

Clinical results of Trial #2

	TREATMENT	(21d-27d)		(27d-40d)		
		GAIN	LESIONS	GAIN	LESIONS	
5	UI/UC/MED	378	1.84	0/0	848	2.20
	UI/UC/DIMED	324	1.97	0/2.4	764	2.34
	UI/C/DIMED	334	1.91	2.4/0.8	719	2.48
	24h-4d	307	1.98	2.0/1.6	734	2.49
10	24h-4d/7d	336	1.90	2.8/2.0	791*	2.26
	24h-48h-4d	301	2.01	3.0/2.2	774	2.32
	24/48h-4d/7d	283	2.26	1.0/0	767	2.37
	24h-248h	250	2.52	1.2/0.4	787#	2.17
	72h-4d	282	2.10	2.2/0.4	781#	2.16
	72h-4d/7d	342	1.82	2.2/1.4	894**	1.98
15						

P<0.05
* P<0.01
** P<0.001

15

* p<0.05

* p<0.01

** p<0.001

Prior to this study, *E. tenebris* had not been

20

used experimentally in this set of ten floor pens, and no

caecal lesions were detected in the UI/UC/Dimed group

(there was a possibility that *E. tenebris* could have been

cycling prior to challenge in the other pens). However,

E. agarryllina was used previously in the same set of

floor pens, and upper intestinal lesions characteristic

of this species were detected in the UI/UC/Dimed group.

Although not statistically significant at 6

days post challenge, only the group receiving the 72

hours antigen 4 day s.c./7 day oral showed weight gain

higher than challenge controls and feed conversions lower

than the medicated control group. Following the 40 day

grow-out, this same 72 hours antigen vaccinated group

46

showed highly significant (p<0.001) protection over

challenge controls in terms of weight gain, and a lower

feed conversion ratio. In addition, the 24 hours antigen

administered s.c. at 4 days followed by the 48 hours

antigen orally at 7 days all elicited significant

protection in terms of weight gain over challenge

controls and comparable or better feed conversions than

the medicated controls following the 40 day grow-out.

The 24 hours 4 day/48 hours 7 day antigen regimen (group

10) as well as the 24/48 hours 4 day s.c./7 day oral

treatment elicited lower intestinal lesion scores 6 days

post challenge. No intestinal lesions were detected

following the grow-out, although a general thickening of

the mucosa was observed in the challenge control group.

It is reasonable to assume that protection against *E.*

tenebris, measured during the grow-out, was elicited in

the presence of cycling *E. agarryllina*.

The following conclusions can be drawn from the

data. Performance protection (weight gains) may be

difficult to measure in floor pens 6 days following

cocyst challenge at 21 days of age. A grow-out to at

least 40 days may be required to demonstrate significant

vaccine efficacy in floor pens.

The 72 hour antigen given once s.c. at 4 day or twice 4 day s.c./7 day oral elicited significant protection over challenge controls. The 72 hours antigen given twice sustained performance comparable to that measured in the medicated control group. This protection was demonstrated in the presence of a 35,000 *E. tenella* challenge and *E. acervulina* cycling in the litter. This is the first demonstration of an inactivated coccidiosis vaccine efficacy in a floor pen system.

The 24/48 hours antigen administered 4 day s.c./7 day oral and the regimen of 24 hours antigen given 4 day s.c. and the 48 hours antigen given 7 day oral elicited the greatest reduction in intestinal lesion scores for both *E. acervulina* and *E. tenella*. This two dose regimen 4 day s.c. followed by 7 day oral appears to be better than a single s.c. immunization at 4 day.

Example 5 - In Vitro Drug Screening

Microcultures of infected cells (in presence of Tr-uacil) were established at time T=0, using log₂ dilutions of alpha-amanitin beginning with 50 µg/ml. Cultures were then harvested at 1 hour, 6 hours, 12 hours, 24 hours and 48 hours post infection, and label incorporation of radioactive precursor was determined by harvesting and processing for scintillation counting.

When alpha-amanitin was present during the first 24 hours of parasitism, incorporation of counts (parasite material) was halted. However, if the alpha-amanitin was added after 24 hours, no inhibition of label incorporation was observed.

Example 6 - Immune Measurements

One-day old inbred chickens (B⁶ and B⁶ × MHC haplotype) (New Hampshire Poultry Research Center), originally derived from the UCD.003 line, were used. Chicks were fed a nonmedicated starter/grower diet and water ad libitum. Birds were used between 1 and 43 days of age.

To simulate natural immunity, one-day old

chicks were immunized with live *E. tenella* (Lilly Strain #65) oocysts for five consecutive days (500 oocysts/day) or artificially immunized at various doses with vaccine

antigens (adjuvanted to 5% Amphigen). Typically, 1- or 4-day old birds were immunized subcutaneously (s.c.) in a 1.0 ml volume at the base of the neck and then boosted with vaccine adjuvanted antigens at 4 or 7 days of age by oral gavage in a 1.0 ml volume. Sham immunized (media plus 5% Amphigen) chickens were used as controls. In some experiments, chickens were challenged at 10 days of age by oral inoculation with 35,000 *E. tenella* oocysts.

49

A. Vaccine and Parasite antigens

Media from *B. hensla* infected F7 cells, collected at 24, 48 and 72 hours post-infection was used as the source of antigen for immunisations and for *in vitro* assays. For immunisations, media collected from infected F7 cells contained 1% FBS and for *in vitro* assays infected media collected was serum-free (0.1% FBS). Antigen-containing media was clarified by centrifugation (800 x g, 30 minutes, 4°C), aliquoted and stored at -20°C until use. All cell-free supernatants (SN's) were quantitated for parasite-specific protein (PSP) using the direct SPZELISA. Fractionated samples were pooled according to PSP and Western reactivity. Sporozoite (SPZ) and merozoite (MZ) antigens were prepared by sonication on ice in serum-free 199 media followed by centrifugation (800 x g, 10 min, 4°C). Protein concentrations were determined by the method of Bradford, *Anal. Biochem.*, 72:248-252 (1976). Sonicated parasite suspensions were adjusted to a final concentration of 10 µg/ml in serum-free Medium 199, aliquoted, and stored at -20°C until use.

B. Cell Isolation

Peripheral blood lymphocytes (PBL) and spleen cells were obtained from naturally or artificially (vaccine)-immunised or immunised/challenged birds at

50

various time points post-immunisation. PBL obtained by cardiac puncture were isolated by Histopaque 1077 (400 x g, 15 minutes, room temperature) centrifugation of heparinised blood samples. In some assays, red blood cells from gradients were also saved and used as co-stimulants for *in vitro* proliferation assays. Single cell spleen suspensions were obtained by disruption of minced tissues by syringe cannulation, followed by slow speed centrifugation (50 x g, 10 minutes, room temperature) and subsequent centrifugation over Histopaque 1077 gradients. Viable cell counts were performed using trypan blue and a haemocytometer.

C. Production of Antigen and Mitogen-

Stimulated Cell Supernatants

Undiluted serum-free antigens, various concentrations of Concanavalin A (Con A) or lipopolysaccharide (LPS), or serum-free Medium 199 (1.0 ml/well) were cultured with lymphocytes at 40°C, 5% CO₂. After 24, 48 and 72 hours supernatants were removed from wells and clarified by centrifugation (800 x g, 15 minutes, room temperature). α -methyl mannoside (α -MM) was added to Con A-containing supernatant to a final concentration of 50 mM. Supernatant samples were aliquoted into 1.5 ml tubes and stored at -80°C until use. Media produced from 0-48 hour (24/48) or 48-72 hour

- (72) post-infection was collected, fractionated by S-Sepharose using a linear NaCl gradient, and pooled based on PEP and Western reactivity. Fraction I represents a pool of 8 fractions taken from the first part of the total fractions collected. Fraction II represents a pool of fractions numbers 9-14 and Fraction III a pool from 15-18.

D. Cell Proliferation Assays

- Ten μ g total protein from each fraction was assayed for reactivity in the cell proliferation assay described below.

- Cells were adjusted to 10^7 cells/ml in complete serum-free Leibovitz's Modified Hahn's media (cLMH) which contains equal parts McCoy's 5A and Leibovitz's media, 5 $\times 10^{-4}$ 2-mercaptoethanol, 5 μ g/ml insulin, 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, 0.25 μ g/ml amphotericin B, 2% tryptose phosphate, and 1 mM sodium pyruvate. Red blood cells (10^7 /ml) were added (0.05 ml/well) to all wells of round-bottomed microtiter plates. Undiluted serum-free antigens, Con A, or serum-free Medium 199 (0.1 ml/well) were thawed in a 37°C water bath and added in quadruplicate, followed by PBL or spleen cells (0.05 ml/well). For mitogen and antigen proliferation assays, cultures were incubated at 40°C, 5% CO₂ for 72 or 96 hours respectively, and then pulsed with

- 1 μ Ci/well [³H]-thymidine (specific activity, 5.0 μ Ci/nmol) during the final 18 hours of culture. Cells were harvested onto glass fiber mats using a MACHIII harvester and radioactivity determined in a Packard Matrix 96 Direct Beta Counter. High and low cpm for each sample were discarded. Except where specified, results were expressed by a stimulation index (S.I.) according to the formula:

$$\text{S.I.} = \frac{\text{mean cpm "immune" cells + antigen}}{\text{mean cpm "naive" cells + antigen}} \quad \text{mean cpm "naive" cells + media}$$

- Splenic lymphocytes from naturally immune birds were found to proliferate in response to E. tenella-infected-biochemically separated fraction II from a S-Sepharose column. Splenic lymphocytes obtained from 25-day old naturally immune birds showed higher S.I. values to fraction II compared to fractions I and III (Table 4).

TABLE 4

Fraction	S.I. Value
24/48 I	1.1
72 I	0.6
24/48 II	2.8
72 II	2.5
24/48 III	2.0
72 III	0.6

K. T-cell Westerns

Pooled fraction 72-II was separated by one-dimensional SDS-PAGE and transferred to nitrocellulose, solubilised and assayed for reactivity in the T-cell Western proliferation assay as described below.

One-dimensional immunoblotting studies were

conducted by using a modification of the method of Lamb and Young, *Immunol.*, 50:1 (1987). Briefly, pooled fractions from 8-sepharose were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) under reducing conditions on 10 or 12.5% acrylamide mini-gels. The separated proteins were transferred to nitrocellulose (pore size, 0.2 μ m) and the nitrocellulose cut into 12 equal sections corresponding to different molecular weight ranges. Nitrocellulose pieces were solubilised according to the method of Abou-Zeid, *J. Imm. Methods*, 28:5 (1987) using DMSO/carbonate-bicarbonate precipitation followed by freeze-thawing in deionised H₂O. Solubilised, microparticulate samples were washed 3x in serum-free DMEM and resuspended in a final volume of 1.0 ml serum-free DMEM. Samples were stored at -20°C until use. For assays, samples were thawed at room temperature, diluted 1:5 in serum-free DMEM, and added in quadruplicate (0.1 ml/well) to round-bottomed microtiter plates containing 5 x 10⁴ red blood cells (0.05 ml/well).

PBL or spleen cells (10⁶ cells/ml, 0.1 ml/well) were then added to plates and cultures incubated at 40°C, 5% CO₂. Cultures were pulsed with 1 μ Ci/well [³H]-thymidine during the final 18 hours of culture, harvested and counted as previously described. Results are expressed as S.I. in Table 5 according to the above formula.

PBL from naturally immune birds also

proliferated in response to a restricted number of λ henella 72-II fractions. PBL obtained from 16-day old naturally-immunised/challenged birds showed the highest S.I. reactivity to three discrete areas of the immunoblot corresponding to antigens of approximate relative molecular weights (kDa) of 68-75, 38-41, and 27-30 kDa (Table 5). Similar parasite proteins of approximate kDa of 25-28 and 38-40 kDa were also identified in crude, concentrated 72 hour antigen by Western using sera from these same naturally-immunised/challenged birds.

TABLE 5

72-II Fraction #	M _r Range(kDa)	S.I. Value
2	97-150	1.2
3	75-97	1.3
4	68-75	2.3
5	55-68	1.1
6	48-55	1.5
7	41-48	1.3
8	38-41	1.9
9	35-38	1.3
10	30-35	1.3
11	27-30	2.5
12	22-26	1.2

F. TNF Assay

Mouse L929 cells [ATCC] were suspended in McCoy's 5A/5% fetal calf serum (FCS) to 4×10^5 cells/ml and 0.1 ml added to flat-bottomed microtiter plates.

- 5 After overnight incubation at 37°C, 5% CO₂, log₁₀ dilutions of mouse recombinant tumor necrosis factor (TNF) standard [Genzyme] (2 µg/ml initial concentration) or test supernatants were prepared in media in the absence or

presence of actinomycin D (2 µg/ml) and added in duplicate to the appropriate wells. Following incubation for 48 hours at 37°C, 5% CO₂, plates were washed IX in Dulbecco's Phosphate-Buffered Saline (DPBS) and cells fixed for 10 minutes at room temperature in

- 15 methanol/acetic acid (3:1). Plates were stained for 10 minutes with 0.5% crystal violet/20% methanol and rinsed several times in dH₂O. After washing, 0.1 ml/well acetic acid (33%) was added and plates allowed to mix on an orbital shaker until stain was uniformly distributed throughout wells. Absorbance of wells at 600 nm was determined in a Molecular Devices V_{max} automated

20 microplate reader. Data is recorded as % cytotoxicity according the formula:

$$\% \text{ cytotoxicity}_A = \lambda_{\text{test}} - \lambda_{\text{media}} / \lambda_{\text{media}}$$

where % cytotoxicity_A represents the amount of cell destruction at a given dilution, λ_{media} represents absorbance in control wells (media alone) and λ_{test} represents absorbance at a given dilution of test supernatant. Titer was defined as the reciprocal of the dilution necessary to achieve 50% cell cytotoxicity.

TABLE 6

Summary of Results from TNF Assay			
	Treatment	Area of Bird Stimulant Cytotoxic Activity*	
10	5 x 500'	10	hrs +
	5 x 500	25	hrs 72h +
			concanavalin A -
15	UI	25	hrs 72h +
			concanavalin A -

* 5 x 500 designates doses of 500 oocysts per day for 5 days.

- (+) designates cytotoxic activity was present but reciprocal titer could not be determined.

G. Interleukin 2 Assay

- 25 IL2 responder cells were isolated from the spleens of naive 2-4 week old B₆D₂ birds. Single cell suspensions were adjusted to 5×10^5 cells/ml in serum-free DMEM containing 2.5 µg/ml Con A and incubated at 40.5°C,

57

5% CO₂ in T-75 flasks. After 48 hours, nonadherent cells were treated with 50mM α -MEM for 20 minutes at 40.5°C and blast cells isolated by centrifugation over Histopaque 1077. Viable cells were resuspended in serum-free cDMEM/100 mM α -MEM to 2x10⁶/ml and added to round-bottomed microtiter plates (0.1 ml/well.) Log₂ dilutions of laboratory standard IL2-containing conditioned media were added in quadruplicate to appropriate wells, and serves as a positive control. Serum-free cDMEM (negative control) or test supernatant were then added (0.1 ml, 25% v/v final well concentration) in quadruplicate and plates incubated at 40°C, 5% CO₂ for 48 hours. Cultures were then pulsed with 1 μ Ci/well [³H]-thymidine for an additional 6 hours. Cells were harvested and counted as previously described. High and low cpm for each sample were discarded. Supernatants considered positive for IL2 are those with mean cpm values at least two-fold that of serum-free control media from each plate.

H. Secondary In Vitro Antibody Assay (SIBA)

Log₂ dilutions of antigen (SPZ, WZ, or cell culture antigens) were prepared in 10 mM borate buffer, pH 9.0, at an initial concentration of 1 μ g PSP/ml and 0.1 ml/well added to Nunc Immuno-Maxisorb ELISA plates.

58

After overnight incubation at 4°C, wells were blocked using PBS/0.05% Tween 20 (PBS-T) containing 5% skim milk (0.2 ml/well) for 2 hours at 37°C. Plates were washed 3X in complete HBSS, 25mM HEPES, pH 7.4, 1X antibiotic/antimycotic (CHBS) and sterilized by UV-irradiation for at least 20 minutes under a sterile hood. PBu or spleen cells were adjusted to 2 x 10⁶ cells/ml and 0.2 ml added to the first column. Log₂ dilutions of cells were then made across the entire plate in serum-free cDMEM (excluding the last column for each plated antigen) to complete the checkerboard titration. Wells were brought up to a final volume of 0.2 ml using a cDMEM and plates incubated for 3 to 5 days at 40.5°C, 5% CO₂. After incubation, plates were vigorously washed 3X using cold PBS-T.

The last column for each plated antigen was incubated with 0.1 ml of *E. tenella* hyperimmune chicken sera (1:2000 in PBS-T/0.05% BSA) for 1 hour at 37°C. After 3X washes in PBS-T, biotinylated goat anti-chicken IgG (1:2000 in PBS-T/2% skim milk) was added to all wells and incubation continued for 1 hour at 37°C. Following 3X washes in PBS-T, wells were treated with horseradish peroxidase labelled streptavidin (1:1000 in PBS-T/2% skim milk) for an additional 1 hour. Plates were thoroughly washed in PBS-T and bound enzyme detected using

TMB/peroxidase substrate. The enzymatic reaction was stopped after 15 minutes by the addition of 1M HCl, and the optical density measured at 450 nm in a Molecular Devices V_{max} automated microplate reader.

5

TABLE 7

Secondary In-Vitro B Cell Assay

Treatment Group	Antigen	OD at 450 nm
5 x 500	72h	1.567
	UI	0.910
	mr2	1.750
UI	72h	0.920
	UI	0.592
	mr2	0.689

10

15

I. Parasite Inhibition Assay (PIA)

The QT-35 cell line (QT35 was provided as a gift from the Department of Veterinary Services, College of Agriculture, Pennsylvania State University), grown in Opti-MEM/1% FBS, was seeded at 1×10^4 cells/well in 96-

20 well flat bottom plates. Following an overnight

incubation at 40°C, 5% CO₂, cells were pretreated with

duplicate log₂ dilutions of positive control conditioned

media or test supernatant. One row was pretreated with

media alone. Following pretreatment for 24 hours, fresh

25 dilutions of test supernatant were added to cells along

with 1×10^4 *X. tsunellia* sporozoites and $1 \mu\text{Ci}$ well¹[H]-uracil. Cultures were incubated for an additional 24 hours, harvested, and counted as described above. A test supernatant was considered positive when a 1:8 dilution caused a 30% reduction in mean cpm compared to untreated controls (media alone).

5

TABLE 8

Parasite Inhibition Assay				
Treatment	Cell Source	Age of Bird	Antigen Stimulation	Inhibition
NE	LPL	15 days	72h No antigen	17%
NE/C	LPL	15 days	72h No antigen	47%
UI/C	LPL	15 days	72h No antigen	40%
			72h No antigen	54%
			72h No antigen	7%
			72h No antigen	43%
Assay controls:				
UI	Spleen	21 days	conA	54%
-	-	-	media alone	0%

20

LPL = Lamina Propria Lymphocytes

NE = Naturally Exposed (500 oocysts given daily for 5 days)

61

Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. For example, use of other appropriate avian pathogens is expected to produce antigens similar to the coccidia antigens described herein. Thus vaccines to pathogens other than coccidia may be designed using the teachings of the above invention. Such modifications and alterations to the compositions and processes of the present invention are believed to be encompassed in the scope of the claims appended hereto.

62

WHAT IS CLAIMED IS:

1. A continuous non-lymphoid cell line capable of replicating the prepatent life cycle of the avian coccidia.
2. The cell line according to claim 1, which is SB-CEV-1\P (ATCC CRL 10497) and clones derived therefrom.
3. The cell line according to claim 2, which is SB-CEV-1\F7 (ATCC CRL 10495) and clones derived therefrom.
4. The cell line according to claim 2, which is SB-CEV-1\G7 (ATCC CRL 10496) and clones derived therefrom.
5. A continuous non-lymphoid cell line capable of replicating the prepatent life cycle of the avian coccidia infected with a selected avian parasite.
6. The cell line according to claim 5 which is SB-CEV-1\P (ATCC CRL 10497) infected with a selected avian parasite.

7. The cell line according to claim 5 which is SB-CEV-1\77 (ATCC CRL 10495) infected with a selected avian parasite.

8. The cell line according to claim 5 which is SB-CEV-1\G7 (ATCC CRL 10496) infected with a selected avian parasite.

9. The cell line according to claim 5 wherein said parasite is from the species *Eimeria*.

10. The cell line according to claim 9 wherein said parasite is *Eimeria tenella*.

11. A continuous non-lymphoid cell line capable of replicating the prepatent life cycle of the avian *Coccidia* transfected with a recombinant DNA molecule encoding an exogenous protein under control of a suitable regulatory sequence capable of directing the replication and expression of said protein in said cell.

12. The cell line according to claim 11, wherein said non-lymphoid cell line is selected from the group consisting of SB-CEV-1\77 (ATCC CRL 10497), SB-CEV-1\77 (ATCC CRL 10495), SB-CEV-1\G7 (ATCC CRL 10496) and clones derived therefrom.

13. An recombinant antigen produced by culturing a continuous non-lymphoid cell line capable of replicating the prepatent life cycle of the avian *Coccidia* transfected with a recombinant DNA molecule encoding an exogenous protein under control of a suitable regulatory sequence capable of directing the replication and expression of said protein in said cell.

14. A method for producing an anti-coccidiosis vaccine comprising culturing a continuous non-lymphoid cell line capable of replicating the prepatent life cycle of the avian *Coccidia* infected with a selected avian parasite, and harvesting cell culture components therefrom.

15. A vaccine component for coccidiosis comprising a pathogenic antigen composition produced by a culturing a continuous non-lymphoid cell line capable of replicating the prepatent life cycle of the avian *Coccidia* infected with a selected avian parasite.

16. The vaccine component according to claim 15 comprising a whole cell extract from the cell line or subfractions thereof.

65

17. The vaccine component according to claim 15 comprising a modified whole cell extract from the cell line or modified subfractions thereof.

18. A vaccine for coccidiosis capable of inducing protection against infection in poultry containing at least one vaccine component for coccidiosis comprising a pathogenic antigen composition produced by culturing a continuous non-lymphoid cell line capable of replicating the prepatent life cycle of the avian *Coccidia* infected with a selected avian parasite, said component in optional association with a suitable carrier or adjuvant.

19. A method for vaccinating poultry against infection by parasites causing coccidiosis involving administering to an animal an effective dose of a vaccine for coccidiosis capable of inducing protection against infection in poultry containing at least one vaccine component for coccidiosis comprising a pathogenic antigen composition produced by culturing a continuous non-lymphoid cell line capable of replicating the prepatent life cycle of the avian *Coccidia* infected with a selected avian parasite, said component in optional association with a suitable carrier or adjuvant.

66

20. A method for producing an avian recombinant antigen by transfecting a continuous non-lymphoid cell line capable of replicating the prepatent life cycle of the avian *Coccidia* with a recombinant DNA molecule encoding an exogenous protein under control of a suitable regulatory sequence capable of controlling the replication and expression of said protein in said cell; and culturing the transfected cell line in suitable culture conditions to produce the recombinant antigen.

21. A method of drug screening for agents which destroy or inhibit the growth of the selected intracellular forms of the parasites comprising exposing a continuous non-lymphoid cell line capable of replicating the prepatent life cycle of the avian *Coccidia* infected with an avian parasite to a selected anti-parasitic agent, and examining any effects on the cell line and parasite activity.

22. A method for replicating the prepatent life cycle *Plasmodium* species of avian *Coccidia* comprising culturing a continuous non-lymphoid cell line capable of replicating the prepatent life cycle of the avian *Coccidia* infected with an *Elmesta* parasite.

23. A method for producing parasite DNA, RNA, or protein from intracellular *Eimeria* structures comprising culturing a continuous non-lymphoid cell line capable of replicating the prepatent life cycle of the avian *Coccidia* infected with an *Eimeria* parasite and recovering said DNA, RNA, or protein from conditioned medium.

24. A method for cultivating growth of a selected pathogen comprising culturing said pathogen in a novel continuous non-lymphoid cell line capable of replicating the prepatent life cycle of the avian *Coccidia*.

INTERNATIONAL SEARCH REPORT

International application No. PCT/US92/05797

<p>A. CLASSIFICATION OF SUBJECT MATTER</p> <p>IPC: G12N 3/00; C07K 3/00; A61K 39/00; C12P 21/06; 1924; C12Q 1/00 US CL: A61K 39/00; G12N 3/00; C07K 3/00; A61K 39/00; C12P 21/06; 1924; C12Q 1/00 According to International Patent Classification (IPC) or to both national classification and IPC</p>																									
<p>B. FIELD(S) SEARCHED</p> <p>Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/940.2, 681, 722, 91; 510/510; 424/18</p>																									
<p>Documentation searched other than minimum documentation to the extent that such documents are indicated in the fields searched</p>																									
<p>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) BIOSIS, BERKELEY, CA, MEDLINE, AFS search terms: <i>Eimeria</i>, <i>coccidia</i>, <i>parasite</i>, <i>cell</i>, <i>culture</i>, <i>protein</i>, <i>vacuole</i>, <i>non-lymphoid</i></p>																									
<p>C. DOCUMENTS CONSIDERED TO BE RELEVANT</p> <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X</td> <td>US, A, 4,630,676 (published at 17 March 1987, see entire document)</td> <td>15-19 14</td> </tr> <tr> <td>X</td> <td>US, A, 4,710,377 (published at 01 December 1987, see entire document)</td> <td>15-19 14</td> </tr> <tr> <td>X</td> <td>US, A, 4,639,372 (Abstract at 27 January 1987, see entire document)</td> <td>15-19 14</td> </tr> <tr> <td>X</td> <td>EP, A, 0,382,531 (Abstract at 16 August 1990, see entire document)</td> <td>15-19 14</td> </tr> <tr> <td>X</td> <td>US, A, 5,029,694 (Abstract at 02 July 1991, see entire document)</td> <td>15-19 14</td> </tr> <tr> <td>X</td> <td>US, A, 4,874,703 (Abstract at 17 October 1989, see entire document)</td> <td>15-19 14</td> </tr> <tr> <td>X</td> <td>Advances in Cell Culture, Volume 3, issued 1987, D. M. Schman et al., "In Vitro Cultivation of the Avian Coccidia", pp. 241-266, see entire document.</td> <td>13,15-19 11,12,20 11-21</td> </tr> </tbody> </table>		Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	US, A, 4,630,676 (published at 17 March 1987, see entire document)	15-19 14	X	US, A, 4,710,377 (published at 01 December 1987, see entire document)	15-19 14	X	US, A, 4,639,372 (Abstract at 27 January 1987, see entire document)	15-19 14	X	EP, A, 0,382,531 (Abstract at 16 August 1990, see entire document)	15-19 14	X	US, A, 5,029,694 (Abstract at 02 July 1991, see entire document)	15-19 14	X	US, A, 4,874,703 (Abstract at 17 October 1989, see entire document)	15-19 14	X	Advances in Cell Culture, Volume 3, issued 1987, D. M. Schman et al., "In Vitro Cultivation of the Avian Coccidia", pp. 241-266, see entire document.	13,15-19 11,12,20 11-21
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																							
X	US, A, 4,630,676 (published at 17 March 1987, see entire document)	15-19 14																							
X	US, A, 4,710,377 (published at 01 December 1987, see entire document)	15-19 14																							
X	US, A, 4,639,372 (Abstract at 27 January 1987, see entire document)	15-19 14																							
X	EP, A, 0,382,531 (Abstract at 16 August 1990, see entire document)	15-19 14																							
X	US, A, 5,029,694 (Abstract at 02 July 1991, see entire document)	15-19 14																							
X	US, A, 4,874,703 (Abstract at 17 October 1989, see entire document)	15-19 14																							
X	Advances in Cell Culture, Volume 3, issued 1987, D. M. Schman et al., "In Vitro Cultivation of the Avian Coccidia", pp. 241-266, see entire document.	13,15-19 11,12,20 11-21																							
<p>* Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.</p>																									
<p><input checked="" type="checkbox"/> Summary of relevant documents</p> <p>* A : Document published in the patent literature of the art which is not considered to be part of prior art.</p> <p>* B : Document published in the patent literature of the art which is not considered to be part of prior art.</p> <p>* C : Document published in the patent literature of the art which is not considered to be part of prior art.</p> <p>* D : Document published in the patent literature of the art which is not considered to be part of prior art.</p> <p>* E : Document published in the patent literature of the art which is not considered to be part of prior art.</p> <p>* F : Document published in the patent literature of the art which is not considered to be part of prior art.</p>																									
<p>Date of the actual completion of the international search: 28 SEPTEMBER 1992</p>																									
<p>Name and mailing address of the ISA/ International Searching Authority PCT Washington, D.C. 20541 Telephone No. NOT APPLICABLE Fax: PCT/US92/05797 (second sheet) 1992</p>																									
<p>Name and mailing address of the ISA/ International Searching Authority PCT Washington, D.C. 20541 Telephone No. NOT APPLICABLE Fax: PCT/US92/05797 (second sheet) 1992</p>																									

INTERNATIONAL RESEARCH REPORT

to: actual applicant No.
PCT/US92/09797

C (Continuation), DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Character of document, with indication, where appropriate, of the relevant passages	Reference to claim No.
X	Isabelle and Lemaire, "Volume 57, No. 3, issued March 1989, C. A. Speer et al., "Building with Immunodeficient P20 Burden Analyses of Human lymphocytes", pp. 999-1001, see entire document.	1-10, 23-24 11-21
Y	Proceedings of the Society for Experimental Biology and Medicine, Volume 197, issued February 1991, S. Chakrabarti et al., "Use of Mouse Monoclonal Cell Lines for In Vivo Propagation of Toxoplasma gondii RH Tachyzoites", pp. 150-157, see pp. 153-154.	21

From PCT/US92/09797 (publication of second international 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)